| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 0 | 21.851 | 24.522 | - | 15.209 | 47.059 | 99.026 | - | - |
| Total Income - EUR | - | 0 | 21.853 | 24.522 | - | 15.209 | 47.059 | 99.026 | - | - |
| Total Expenses - EUR | - | 0 | 11.009 | 29.255 | - | 14.830 | 14.718 | 20.297 | - | - |
| Gross Profit/Loss - EUR | - | 0 | 10.845 | -4.733 | - | 379 | 32.341 | 78.729 | - | - |
| Net Profit/Loss - EUR | - | 0 | 10.604 | -4.895 | - | 379 | 32.341 | 78.729 | - | - |
| Employees | - | 0 | 2 | 2 | - | 2 | 2 | 2 | - | - |
Check the financial reports for the company - Promicron Plus Srl-D
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 0 | 925 | 786 | - | 520 | 394 | 279 | - | - |
| Current Assets | - | 45 | 15.098 | 15.618 | - | 37.485 | 75.343 | 157.498 | - | - |
| Inventories | - | 0 | 2.507 | 1.842 | - | 4.649 | 7.337 | 22.677 | - | - |
| Receivables | - | 0 | 4.006 | 11.029 | - | 13.703 | 24.027 | 39.877 | - | - |
| Cash | - | 45 | 8.584 | 2.747 | - | 19.133 | 43.978 | 94.945 | - | - |
| Shareholders Funds | - | 45 | 10.648 | 5.195 | - | 16.521 | 48.495 | 127.374 | - | - |
| Social Capital | - | 45 | 44 | 43 | - | 41 | 40 | 41 | - | - |
| Debts | - | 0 | 5.375 | 11.208 | - | 21.485 | 27.241 | 30.403 | - | - |
| Income in Advance | - | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2562 - 2562" | |||||||||
| CAEN Financial Year |
2562
|
|||||||||
Comments - Promicron Plus Srl-D